Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspire Medical Systems ( (INSP) ) just unveiled an announcement.
On August 11, 2025, Inspire Medical Systems announced that its Board of Directors authorized a share repurchase program of up to $200 million. This decision reflects the company’s confidence in its growth prospects and the belief that its stock is undervalued. The repurchase program is part of a broader strategy to support the launch of Inspire V, their next-generation neurostimulation system, and to return capital to shareholders while continuing to invest in future growth.
The most recent analyst rating on (INSP) stock is a Hold with a $200.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Spark’s Take on INSP Stock
According to Spark, TipRanks’ AI Analyst, INSP is a Neutral.
Inspire Medical Systems’ overall stock score is driven by strong financial performance and promising corporate developments. However, technical analysis indicates bearish momentum, and valuation metrics suggest the stock is overvalued. Mixed sentiment from the earnings call, with reduced guidance, also impacts the score.
To see Spark’s full report on INSP stock, click here.
More about Inspire Medical Systems
Inspire Medical Systems, Inc. is a medical technology company that focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea. Their proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.
Average Trading Volume: 834,264
Technical Sentiment Signal: Sell
Current Market Cap: $2.34B
Learn more about INSP stock on TipRanks’ Stock Analysis page.